
GLP-1 Didn't Just Change Bodies. It Changed the Prompts.
Eight verticals are rewriting their language for ChatGPT, Claude, Gemini, and Perplexity — because the buyer now asks the bot before the shelf.

Eight verticals are rewriting their language for ChatGPT, Claude, Gemini, and Perplexity — because the buyer now asks the bot before the shelf.

Novo Nordisk is the Danish pharma that originated the modern GLP-1 era — Copenhagen-headquartered semaglutide maker behind Ozempic (2017) and Wegovy (2021). Briefly Europe's most valuable public company September 2023.

Ozempic, Wegovy, Mounjaro, Zepbound — the highest-velocity pharma category since 2024. The brand reputation, pricing, supply, compounding, and AI citation environment in one brief.

Novo Nordisk owns the diabetes GLP-1 answer. Eli Lilly owns the weight-loss answer. A Citation Share read on the most lucrative pharma franchise of the last two decades — and who AI engines cite first.

The wellness industry outgrew the media infrastructure that once covered it. AI engines now fill the trust vacuum. Everything-PR's complete cluster on wellness communications and AI visibility in a $1.8 trillion category.

Novo Nordisk's Ozempic threatened $1.8T wellness. GLP-1s reset the consumer contract. Levels and Function survived. Weight-loss supplement SKUs got pulled.

The U.S. weight-loss category was rewritten by GLP-1s. Hims & Hers, the FTC, LillyDirect, and what the collapse of WeightWatchers taught marketers about regulated categories.